Make your money go further for just 25p per day

Podcasts

More than Money: Shield Therapeutics

We talk nasty shocks, drugs approvals and the value of patience with Shield Therapeutics' founder and chief executive Carl Sterritt

Access the full Investor’s Champion Portfolio

Register to view the full portfolio which can be bought via our associates at Fundamental Asset.

Get FREE access now

Already a member? Login

For access to the top news and insights from the investment world

REGISTER FREE TODAY

Our MORNING EMAIL delivers the daily news you need to make your money go further straight into your inbox.

SIGN UP
News & Insights

M&S and Royal Mail: Is it too late to turn things around?

22/05/2019
Investors Clinic
PREMIUM

Dividend dogs vs diamonds: Part 1 – beware the yield

21/05/2019
Investors Clinic
PREMIUM

ESG investment: Are plants the future of food?

17/05/2019

Search for AIM companies qualifying for relief from Inheritance Tax!

Use our unique screening tool to identify Inheritance Tax planning AIM companies

This search will take you to the separate AIMsearch web site which requires a different user name and password to this Investor's Champion site.

News & Insight


Vodafone cuts dividend: are the shares still worth holding?

14/05/2019

Scapa Group - Bonkers valuation of the week

21/05/2019

Can Sainsbury’s recover from its Asda disappointment?

02/05/2019

Ride hailing – the S-Uber-b way

03/04/2019

Money Management


Reviewing the robo-advisers

21/03/2019

Busting the myths of the independent financial adviser industry

09/05/2019

Robo-wars: Investec axes Click & Invest

16/05/2019

Help to Buy: has it worked?

26/02/2019

Companies Analysed


PREMIUM

Portfolio Flash News: May

20/05/2019
PREMIUM

Should investors take a slice of Domino’s Pizza US?

13/05/2019

Should investors be worried about social consciousness?

28/03/2019
PREMIUM

What can Lyft teach us about tech IPOs in 2019?

03/04/2019

LATEST FROM INVESTOR'S CHAMPION

M&S and Royal Mail: Is it too late to turn things around?

22/05/2019 · Marks & Spencer · Ocado · Royal Mail
Marks & Spencer and Royal Mail - two former British icons - are both facing an uphill battle as they attempt to win back customers in the age of Amazon.

More than Money: Shield Therapeutics

22/05/2019 · Shield Therapeutics PLC
We talk nasty shocks, drugs approvals and the value of patience with Shield Therapeutics' founder and chief executive Carl Sterritt

Scapa Group - Bonkers valuation of the week

21/05/2019 · Scapa Group
Scapa Group trades at a premium valuation yet generates relatively modest real cash returns

Dividend dogs vs diamonds: Part 1 – beware the yield

Vodafone’s cut is proof that it is right to fear shares which yield over 8%

Portfolio Flash News: May

20/05/2019
Sage reels in benefits from demand for recurring software subscriptions

ESG investment: Are plants the future of food?

Beyond Meat is worth more than $5bn – investors are betting on a meat-free future

There are plenty of reasons to register at Investor's Champion

Register free to gain access to more research

Register today

Here's what people say

S.F.
Just wanted to pass on my thanks for your value-adding blogs. In particular it was through your blog that I first became aware of Van Elle Holdings and prompted me to have a good look at them.
P.E.
Excellent analysis of one of many AIM abuses, well done!
G.M.
Nicely written!
Keep it coming guys
D.D.
Many thanks for a really honest bit of research!! I agree it is hard to see the attraction and with the flak the chairman has been getting for abusing his "royal" position I'll definitely give this one a miss.